Tuberculosis, caused by the pathogen Mycobacterium tuberculosis, is one of the world’s deadliest bacterial infectious disease. It is still a global-health threat, particularly because of the drug-resistant forms. Fluoroquinolones, with target of gyrase, are among the drugs used to treat tuberculosis. However, their widespread use has led to bacterial resistance. The molecular mechanisms of fluoroquinolone resistance in mycobacterium tuberculosis have been reported, such as DNA gyrase mutations, drug efflux pumps system, bacterial cell wall thickness and pentapeptide proteins (MfpA) mediated regulation of gyrase. Mutations in gyrase conferring quinolone resistance play important roles and have been extensively studied. Recent studies have shown that the regulation of DNA gyrase affects mycobacterial drug resistance, but the mechanisms, especially by post-translational modification and regulatory proteins, are poorly understood. In this review, we summarize the fluoroquinolone drug development, and the molecular genetics of fluoroquinolone resistance in mycobacteria. Comprehensive understanding of the mechanisms of fluoroquinolone resistance in Mycobacterium tuberculosis will open a new view on understanding drug resistance in mycobacteria and lead to novel strategies to develop new accurate diagnosis methods.
[1] Ginsburg AS, Grosset JH, Bishai WR. Fluoroquinolones, tuberculosis, and resistance. Lancet Infect Dis , 2003, 3(7): 432-442.
[2] Gandhi NR, Nunn P, Dheda K, Schaaf HS, Zignol M, van Soolingen D, Jensen P, Bayona J. Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. Lancet , 2010, 375(9728): 1830-1843.
[3] Manjelievskaia J, Erck D, Piracha S, Schrager L. Drug- resistant TB: deadly, costly and in need of a vaccine. Trans Roy Soc Trop Med Hyg , 2016, 110(3): 186-191.
[4] Marks SM, Flood J, Seaworth B, Hirsch-Moverman Y, Armstrong L, Mase S, Salcedo K, Oh P, Graviss EA, Colson PW, Armitige L, Revuelta M, Sheeran K. Treatment practices, outcomes, and costs of multidrug-resistant and extensively drug-resistant tuberculosis, United States, 2005-2007. Emerg Infect Dis , 2014, 20(5): 812-821.
[5] O'Donnell MR, Jarand J, Loveday M, Padayatchi N, Zelnick J, Werner L, Naidoo K, Master I, Osburn G, Kvasnovsky C, Shean K, Pai M, Van der Walt M, Horsburgh CR, Dheda K. High incidence of hospital admissions with multidrug-resistant and extensively drug-resistant tuberculosis among South African health care workers. Ann Intern Med , 2010, 153(8): 516-522.
[6] Nuermberger E, Tyagi S, Tasneen R, Williams KN, Almeida D, Rosenthal I, Grosset JH. Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis. Antimicrob Agents Chemother , 2008, 52(4): 1522-1524.
[7] Veziris N, Ibrahim M, Lounis N, Andries K, Jarlier V. Sterilizing activity of second-line regimens containing TMC207 in a murine model of tuberculosis. PLoS One , 2011, 6(3): e17556.
[8] Takiff H, Guerrero E. Current prospects for the fluoroquinolones as first-line tuberculosis therapy. Antimicrob Agents Chemother , 2011, 55(12): 5421-5429.
[9] An DD, Duyen NTH, Lan NTN, Hoa DV, Ha DTM, Kiet VS, Thu DDA, Van Vinh Chau N, Dung NH, Sy DN, Farrar J, Caws M. Beijing genotype of Mycobacterium tuberculosis is significantly associated with high-level fluoroquinolone resistance in Vietnam. Antimicrob Agents Chemother , 2009, 53(11): 4835-4839.
[10] Sun ZG, Zhang JY, Zhang XX, Wang SM, Zhang Y, Li CY. Comparison of gyrA gene mutations between laboratory-selected ofloxacin-resistant Mycobacterium tuberculosis strains and clinical isolates. Int J Antimicrob Agents , 2008, 31(2): 115-121.
[11] Lesher GY, Froelich EJ, Gruett MD, Bailey JH, Brundage RP. 1, 8-naphthyridine derivatives. A new class of chemotherapeutic agents. J Med Chem , 1962, 5(5): 1063-1065.
[12] Emmerson AM, Jones AM. The quinolones: decades of development and use. J Antimicrob Chemother , 2003, 51 (Suppl. 1): 13-20.
[13] Sullivan EA, Palumbo L, Ebrahimzadeh A, Frieden TR, Sullivan EA, Frieden TR, Kreiswirth BN, Kapur V, Musser JM. Emergence of fluoroquinolone-resistant tuberculosis in New York City. Lancet , 1995, 345(8958): 1148-1150.
[14] Ängeby KA, Jureen P, Giske CG, Chryssanthou E, Sturegård E, Nordvall M, Johansson AG, Werngren J, Kahlmeter G, Hoffner SE, Schön T. Wild-type MIC distributions of four fluoroquinolones active against Mycobacterium tuberculosis in relation to current critical concentrations and available pharmacokinetic and pharmacodynamic data. J Antimicrob Chemother , 2010, 65(5): 946-952.
[15] Shandil RK, Jayaram R, Kaur P, Gaonkar S, Suresh BL, Mahesh BN, Jayashree R, Nandi V, Bharath S, Balasubramanian V. Moxifloxacin, ofloxacin, sparfloxacin, and Ciprofloxacin rofloxacin against Mycobacterium tuberculosis : evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy. Antimicrob Agents Chemother , 2007, 51(2): 576-582.
[16] Yadav V, Deopujari K. Gatifloxacin and dysglycemia in older adults. New Engl J Med , 2006, 354(25): 2725-2726.
[17] Renau TE, Gage JW, Dever JA, Roland GE, Joannides ET, Shapiro MA, Sanchez JP, Gracheck SJ, Domagala JM, Jacobs MR, Reyn
